Literature DB >> 31437340

Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration.

Ekaterina A Lysikova1,2, Michail S Kukharsky2, Kirill D Chaprov1,2, Nataliia A Vasilieva2, Andrei Y Roman2, Ruslan K Ovchinnikov2, Alexey V Deykin3, Natalia Ninkina1,2, Vladimir L Buchman1,2.   

Abstract

Multiple clinical and experimental evidences suggest that amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are members of a disease continuum. Pathological inclusions of fused in sarcoma (FUS) protein have been observed in subsets of patients with these diseases but their anatomical distribution is different for two diseases. These structures are present in motor neurons in ALS cases but in cortical neurons in FTLD cases. Expression of a C-terminally truncated form of human FUS causes an early onset and progressive motor neuron pathology in transgenic mice but only when these neurons express a certain level of this protein. Severe motor dysfunction and early lethality of mice with expression above this level prevent their use for studies of FTLD-related pathology caused by expression of this form of FUS. In the present study, we used another line of mice expressing the same protein but not developing any signs of motor system dysfunction due to substantially lower level of transgene expression in motor neurons. In a set of tests 5-month old mice displayed certain behavioural abnormalities, including increased impulsivity, decreased anxiety and compromised social interaction, which recapitulate behaviour characteristics typically seen in FTLD patients.
© 2019 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  FUS; cognitive impairments; frontotemporal dementia; frontotemporal lobar degeneration; transgenic animals

Mesh:

Substances:

Year:  2019        PMID: 31437340     DOI: 10.1111/gbb.12607

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  4 in total

1.  Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.

Authors:  Johannes de Munter; Diana Babaevskaya; Erik Ch Wolters; Dmitrii Pavlov; Ekaterina Lysikova; Allan V Kalueff; Anna Gorlova; Margarita Oplatchikova; Igor A Pomytkin; Andrey Proshin; Aleksei Umriukhin; Klaus-Peter Lesch; Tatyana Strekalova
Journal:  J Cell Mol Med       Date:  2020-07-15       Impact factor: 5.310

2.  A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice.

Authors:  Kirill Chaprov; Alexander Rezvykh; Sergei Funikov; Tamara A Ivanova; Ekaterina A Lysikova; Alexei V Deykin; Michail S Kukharsky; Alexey Yu Aksinenko; Sergey O Bachurin; Natalia Ninkina; Vladimir L Buchman
Journal:  CNS Neurosci Ther       Date:  2021-03-23       Impact factor: 5.243

Review 3.  Genetic architecture of common non-Alzheimer's disease dementias.

Authors:  Rita Guerreiro; Elizabeth Gibbons; Miguel Tábuas-Pereira; Celia Kun-Rodrigues; Gustavo C Santo; Jose Bras
Journal:  Neurobiol Dis       Date:  2020-05-19       Impact factor: 5.996

4.  Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice.

Authors:  Johannes P J M de Munter; Igor Shafarevich; Alexei Liundup; Dmitrii Pavlov; Erik Ch Wolters; Anna Gorlova; Ekaterina Veniaminova; Aleksei Umriukhin; Allan Kalueff; Andrei Svistunov; Boris W Kramer; Klaus-Peter Lesch; Tatyana Strekalova
Journal:  CNS Neurosci Ther       Date:  2019-12-23       Impact factor: 5.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.